Close Menu

NEW YORK (GenomeWeb) – MDxHealth reported Thursday that its total full-year 2017 revenues rose 35 percent, led by sales of its ConfirmMDx for prostate cancer test, which accounted for 91 percent of sales volumes.

For the 12 months ended Dec. 31, the company reported total revenues of $40.5 million, up from $30.0 million in 2016. Revenue included the sale of the company's colorectal cancer patents to Exact Sciences. Excluding revenue from that sale for both periods, total products and services revenue rose approximately 13 percent to $28.2 million during 2017.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A new analysis suggests warming, not the arrival of humans, led to the extinction of the woolly rhinoceros thousands of years ago, the Economist reports.

Chinese health officials uncovered SARS-CoV-2 viral RNA on imported frozen food, but the New York Times reports catching COVID-19 that way would be unlikely.

The UK has ordered 60 million coronavirus vaccine doses from Novavax and 30 million doses from Janssen, according to the Guardian.

In Science this week: machine learning model predicts whether ion channel mutations will cause disease, and more.